A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 432 participants.

Also called NCT02504294

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 3
Enrolled
  • 432 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02504294
Other papers using this trial's data
  • Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis American journal of nephrology, 2018 DOI, PubMed 30196301, PMC6214608 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02504294. Randomized; no masking; primary purpose other. Start 2015-07-13 (actual); primary completion 2016-07-02 (actual). Results posted on 2018-06-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
Intervention (Biological)
Epoetin Hospira Arm
Intervention (Other)
Standard of Care Arm
Intervention (Drug)
IV Iron
Lead sponsor
Pfizer (class: industry)
Collaborator
Hospira, now a wholly owned subsidiary of Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02504294
Content hash
dd64f1b13e31494742946221491bde88693627f278943456dceec7e86307d46f